Fosbretabulin disodium

Research use only, not for human use.

A derivative of combretastatin that acts as a microtubule destabilising agent.

A derivative of combretastatin that acts as a microtubule destabilising agent; damage the vasculature (blood vessels) of cancer tumours causing central necrosis.Chemotherapeutic Agents Phase 3 Clinical(In Vitro):Fosbretabulin disodium inhibits growth of leukemia P-388, pancreas BXPC-3, neuroblast SK-N-SH, thyroid SW1736, lung-NSC NCI-H460, prostate DU-145, an pharynx FADU, with EC50s of 0.0029, 0.23, 0.00025, 0.00061, 0.00035, 0.00072, and 0.00045 μg/mL, respectively.(In Vivo):Fosbretabulin disodium (100 mg/kg; i.p.) increases the mean arterial blood pressure (MABP) at 1 and 6 h after administration and decreases the tumor blood flow in rats.

——

Animal Model:Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumorDosage:100 mg/kg Administration:A single i.p. injections Result:Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration.Reduced the blood flow in the tumor.

CA4DP | CA4P | Combretastatin A-4 phosphate

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

Tubulin

Cancer

Chemotherapeutic

168555-66-6

440.292

C18H19Na2O8P

>98% (HPLC)

H2O: 4.4 mg/mL (Need ultrasonic and warming); DMSO: < 0.044 mg/mL

COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)OP(=O)([O-])[O-].[Na+].[Na+]

Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 1-(dihydrogen phosphate), sodium salt (1:2)

(-20℃)

With Ice Pack

≥ 2 years